ErbB2/Her2 Products

Description

ErbB2/HER2 is one of the four members of the ErbB receptor family of transmembrane receptor-like tyrosine kinases (1). The kinase activity of ErbB2 can be activated without ligand if it is overexpressed, and by association with other ErbB proteins (2). Overexpression of ErbB2 is detected in almost 40% of human breast cancers (3). Binding of c-Cbl ubiquitin ligase to Tyr1112 of ErbB2 leads to poly-ubiquitination of ErbB2 and enhances its degradation (4). ErbB2 is one of the major targets for the treatment of breast cancer and other carcinomas.

Bioinformatics

Product By Gene ID

2064

Alternate Names

CD340 antigen CD340 c-erb B2/neu protein EC 2.7.10 EGFR2 ErbB2 HER2 HER-2 HER2EC 2.7.10.1 herstatin Metastatic lymph node gene 19 protein MLN 19 MLN19 Neu Oncogene NEUHER-2/neu neuroblastoma/glioblastoma derived oncogene homolog NGL NGLTKR1 p185erbB2 Proto-oncogene c-ErbB-2 Proto-oncogene Neu receptor tyrosine-protein kinase erbB-2 TKR1 Tyrosine kinase-type cell surface receptor HER2 v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2(neuro/glioblastoma derived oncogene homolog) v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastomaderived oncogene homolog (avian)

Research Areas for ErbB2/Her2

Find related products by research area and learn more about each of the different research areas below.

Breast Cancer
Cancer
Cellular Markers
Core ESC-Like Genes
Oncogenes
Phospho-Specific
Protein Kinase
Stem Cell Markers
Tumor Suppressors

Related ErbB2/Her2 Blog Posts

Check out the latest blog posts on ErbB2/Her2.

Unlocking the Potential of Biosimilars in Immuno-Oncology By Jennifer Jones, M.S.Biosimilar Antibodies: Imitation Meets InnovationIn the ever-evolving medical landscape, a new class of pharmaceuticals is emerging as a game-changer, poised to transform the way we approach...    Read more.

NPC1: A Potential Target For Triple-Negative Breast Cancer By Natalia Gurule, PhD Breast Cancer is a Heterogeneous DiseaseBreast cancer is the most frequently identified malignancy in women, accounting for 30% of diagnosed cases of cancer in women in the US annuall...    Read more.

Hypoxia-Dependent CAR Stabilizing Construct in T cells Improves Solid Tumor Targeting and Efficacy By Victoria Osinski, PhDDespite advances in the development of cancer immunotherapies, those specifically targeting tumors still remains limited. Currently, there is great interest in utilizing chimeric antigen rece...    Read more.

Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy By Victoria Osinski, PhDWhat’s “Natural” About Natural Killer (NK) Cells?For immunologists, the term cytotoxicity often conjures up images of an army of antigen specific CD8+ T cells deploying to ...    Read more.

Read more ErbB2/Her2 related blogs.